Related Experiment Video

Updated: May 12, 2026

Induction and Validation of Cellular Senescence in Primary Human Cells
08:18

Induction and Validation of Cellular Senescence in Primary Human Cells

Published on: June 20, 2018

Cellular senescence in cancer treatment: friend or foe?

Pascal Kahlem1, Bernd Dörken, Clemens A Schmitt

  • 1Department of Hematology, Oncology, and Tumor Immunology, Humboldt University, Charité, Berlin, Germany.

The Journal of Clinical Investigation
|January 15, 2004
PubMed

Insights

Anticancer therapies targeting DNA can induce premature senescence, a cellular response. This review explores whether inducing senescence is beneficial or detrimental to cancer treatment outcomes.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • DNA damage is a primary mechanism for anticancer therapies.
  • Therapeutic interventions can trigger programmed cellular responses, including apoptosis and premature senescence.
  • Premature senescence is a recognized drug-responsive program influencing cancer therapy efficacy.

Purpose of the Study:

  • To discuss the dual role of therapy-induced premature senescence in cancer treatment.
  • To evaluate whether senescence induction is a beneficial or detrimental outcome of anticancer interventions.

Main Methods:

  • This study is a review and discussion of existing research.
  • Analysis of literature on DNA damage response and cellular senescence in cancer therapy.

Main Results:

  • Therapy-mediated premature senescence is a significant cellular response to anticancer drugs.
  • The impact of senescence induction on cancer therapy outcomes requires careful consideration.

Conclusions:

  • The role of senescence in cancer therapy is complex and context-dependent.
  • Further research is needed to determine if senescence induction is a favorable or unfavorable consequence of cancer treatment.

More Related Videos

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

Related Concept Videos

Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...